DekaBank Deutsche Girozentrale
INO icon

DekaBank Deutsche Girozentrale’s Inovio Pharmaceuticals INO Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,092
Closed -$108K – 1405
2022
Q2 		$108K Hold
5,092
– – ﹤0.01% 1272
2022
Q1 		$223K Buy
5,092
+467
+10% +$21K ﹤0.01% 1189
2021
Q4 		$285K Buy
4,625
+125
+3% +$10K ﹤0.01% 1207
2021
Q3 		$400K Hold
4,500
– – ﹤0.01% 1097
2021
Q2 		$488K Hold
4,500
– – ﹤0.01% 1071
2021
Q1 		$476K Hold
4,500
– – ﹤0.01% 1038
2020
Q4 		$478K Sell
4,500
-208
-4% -$27.7K ﹤0.01% 1029
2020
Q3 		$633K Buy
+4,708
New +$982K ﹤0.01% 878
2019
Q4 		– Sell
-2,492
Closed -$63K – 1176
2019
Q3 		$63K Sell
2,492
-2,491
-50% -$75.7K ﹤0.01% 935
2019
Q2 		$175K Buy
4,983
+1,950
+64% +$77.5K ﹤0.01% 1032
2019
Q1 		$184K Buy
3,033
+541
+22% +$27.3K ﹤0.01% 1049
2018
Q4 		$118K Sell
2,492
-541
-18% -$32.9K ﹤0.01% 1044
2018
Q3 		$184K Sell
3,033
-84
-3% -$4.68K ﹤0.01% 1072
2018
Q2 		$145K Hold
3,117
– – ﹤0.01% 1081
2018
Q1 		$176K Sell
3,117
-300
-9% -$16.2K ﹤0.01% 1003
2017
Q4 		$226K Hold
3,417
– – ﹤0.01% 930
2017
Q3 		$226K Hold
3,417
– – ﹤0.01% 936
2017
Q2 		$325K Hold
3,417
– – ﹤0.01% 891
2017
Q1 		$268K Sell
3,417
-291
-8% -$23.2K ﹤0.01% 816
2016
Q4 		$313K Buy
3,708
+291
+9% +$26.3K ﹤0.01% 749
2016
Q3 		$380K Hold
3,417
– – ﹤0.01% 718
2016
Q2 		$387K Buy
3,417
+875
+34% +$106K ﹤0.01% 722
2016
Q1 		$263K Sell
2,542
-500
-16% -$38.6K ﹤0.01% 788
2015
Q4 		$256K Buy
3,042
+42
+1% +$3.34K ﹤0.01% 822
2015
Q3 		$208K Buy
3,000
+167
+6% +$14.6K ﹤0.01% 860
2015
Q2 		$277K Buy
2,833
+458
+19% +$48.9K ﹤0.01% 809
2015
Q1 		$233K Buy
+2,375
New +$230K ﹤0.01% 870

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

DekaBank Deutsche Girozentrale's INO Position: Q3 2022 in Review

DekaBank Deutsche Girozentrale sold out of Inovio Pharmaceuticals (INO) in Q3 2022, closing a stake of 5,092 shares — an estimated $108K sold.

DekaBank Deutsche Girozentrale first reported a position in INO in Q1 2015 and held it in 27 quarters. The position peaked at $633K in Q3 2020. 182 funds tracked by Wall St. Rank hold INO as of Q3 2022.

  • DekaBank Deutsche Girozentrale reported no remaining Inovio Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 5,092 Inovio Pharmaceuticals shares in Q3 2022, an estimated $108K.
  • DekaBank Deutsche Girozentrale first reported a position in Inovio Pharmaceuticals in Q1 2015 and held it in 27 quarters.
  • DekaBank Deutsche Girozentrale's Inovio Pharmaceuticals position peaked at $633K in Q3 2020.
  • 182 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q3 2022, filed 2 Nov 2022.